Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook

Published 4 days ago Negative
Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook
Auto
Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Continue Reading

View comments

More News

Rocket RKT Q3 2025 Earnings Call Transcript

1 hour ago Positive

How the SAP Story Is Shifting as Analysts Weigh Cloud Growth and Revenue Headwinds

1 hour ago Negative

Urban One (UONE) Q3 2025 Earnings Call Transcript

1 hour ago Negative

CeriBell (CBLL) Q3 2025 Earnings Call Transcript

1 hour ago Positive

New Benchmark from CCM Institute Warns 80% of Businesses Lack Clear Contract Accountability

1 hour ago Positive